Osi Pharmaceuticals files sNDA for lung cancer drug
March 25th, 2009
Osi Pharmaceuticals, a biotechnology company, and Genentech, have announced that Osi has submitted a supplemental new drug application to the FDA for the use of Tarceva as a first-line maintenance therapy for people with advanced non-small cell lung cancer who have not progressed following first-line treatment with platinum-based chemotherapy.